Anxiety that wasn't there a year ago
8 min read · Uplevel editorial
You've managed difficult things without your body turning against you. Job losses, relationship endings, health scares, the accumulated weight of a life with no shortage of hard passages. You're not someone who catastrophizes. You've always been able to sit with uncertainty without it becoming a physical event. So when the heart racing at rest started — or the sense of dread that didn't attach to anything specific, or waking at 4 a.m. with your body braced for something that isn't there — you noticed it was different. Not anxiety the way you understood anxiety. Something running without content. Your nervous system in a state of readiness with no object to be ready for.
The conventional response, when you describe this, tends to be quick. Everyone's stressed. Try mindfulness. Here's a referral to therapy, which may well be worth taking, but is being offered as though it's the whole answer. Sometimes: here's a prescription for an SSRI. The conversation rarely lingers on the word "new." New anxiety — anxiety that has emerged in a person who didn't have this problem, in a body that is a decade older than it was the last time things were fine — is a different clinical situation than chronic anxiety that has been a part of someone's constitution for their whole life. Treating them identically is how the physiological drivers of new-onset anxiety go uninvestigated for years.
Anxiety that appears in midlife — particularly but not exclusively in women in their forties and men in their fifties and sixties — more often has a physiological driver than primary anxiety presenting earlier in life, and investigating those drivers is the appropriate first response. Not instead of addressing the anxiety symptom, which is real and disruptive, but as the substrate that anxiety management has to work with. Symptom management on top of an unaddressed driver is an ongoing tax.
The perimenopause mechanism deserves to be named specifically because it is dramatically underappreciated outside of women's health specialty. Progesterone, as it declines in perimenopause, takes with it its metabolite allopregnanolone — a neurosteroid that binds GABA-A receptors and has pronounced anxiolytic and calming effects. The withdrawal of allopregnanolone from a nervous system that has been calibrated to its presence for decades is not a trivial event. It is, mechanistically, somewhat similar to GABA-A withdrawal in a general sense — the baseline inhibitory tone of the nervous system decreases. Women in perimenopause who develop new anxiety, new irritability, new sensitivity to stress, or new trouble sleeping are frequently experiencing a neurosteroid withdrawal effect that predates any mood disorder, that can emerge years before conventional menopause, and that is rarely explained to them in these terms. It is often attributed to life stress, which may be coincidentally true and is still not the mechanism.
Thyroid dysregulation is another driver that frequently goes underdiagnosed. Hyperthyroid states — including subclinical hyperthyroidism, where TSH is suppressed but thyroid hormones are still technically in range — produce symptoms that overlap almost completely with anxiety: elevated heart rate, palpitations, heat intolerance, tremor, nervousness, difficulty concentrating, sleep disruption. Hashimoto's thyroiditis, the most common autoimmune thyroid condition, can produce a flare-and-ebb pattern where thyroid hormone is transiently elevated by tissue inflammation before the eventual hypothyroid trajectory asserts itself. The fluctuating thyroid of an active Hashimoto's process can produce anxiety symptoms that come and go in a pattern that looks, from the outside, like generalized anxiety disorder. TSH alone does not capture this — free T3, free T4, and thyroid antibody testing complete the picture.
Autonomic dysregulation — POTS, dysautonomia, inappropriate sinus tachycardia — produces physical anxiety symptoms without psychological anxiety content, and is one of the most frequently missed explanations for new-onset heart racing, dizziness, and sense-of-dread presentations in people who previously had none of these. Post-viral autonomic dysfunction, in particular, has received substantially more attention since COVID — a significant proportion of people with prolonged post-viral syndromes develop autonomic dysregulation that produces precisely this presentation. A person who had a viral illness eighteen months ago and has had new anxiety symptoms since then may not be presenting with a psychological response to the illness. They may be presenting with the autonomic sequelae of the illness, which is a different mechanism requiring a different investigation.
Cardiovascular causes of apparent anxiety are worth considering in midlife specifically. Cardiac arrhythmias — particularly paroxysmal atrial fibrillation, which can feel exactly like palpitations-with-dread — are worth ruling out when the presentation includes heart racing at rest or episodic. Blood sugar dysregulation, including the reactive hypoglycemia that can occur in metabolically shifting midlife adults, produces adrenaline-driven arousal states that feel identical to anxiety from the inside. The adrenaline counterregulatory response to a glucose dip — heart racing, a sense that something is wrong, hyperalertness — occurs without any psychological content and is frequently interpreted as anxiety rather than investigated as a metabolic event.
Medications require honest review. An SSRI that has been on board for several years can, in some people and through poorly understood mechanisms, begin producing agitation or worsening anxiety rather than managing it — the same class of medication that can help anxiety can sometimes become a contributor to it. Stimulants for ADHD, dosing changes, or tolerance shifts can produce or worsen anxiety. Certain antihistamines, certain antihypertensives, alcohol pattern changes in a tolerance-shifting midlife physiology — these are worth mapping against the timeline of the anxiety onset. The question "what changed approximately twelve months ago" sometimes has an answer that is pharmacological.
The conventional workup that should happen when anxiety is new includes thyroid function beyond just TSH, sex hormones with attention to perimenopause status in women, basic cardiovascular evaluation if there are palpitations or any cardiac-adjacent symptoms, blood glucose and insulin dynamics if there's reason to suspect metabolic involvement, a post-viral history that is taken seriously if there's a relevant timeline, and a medication review that doesn't treat current prescriptions as a fixed background. This is more than many people get, and getting it requires a provider who treats "new anxiety in a midlife adult" as a diagnostic presentation rather than a foregone conclusion.
The foundational interventions that address physiological drivers — not just symptom management — are upstream of any supplementation or medication approach. For women in perimenopause, the progesterone question is load-bearing: progesterone restoration, where indicated and appropriate for the individual's full context and their prescribing provider's assessment, directly addresses the neurosteroid mechanism that may be driving the baseline shift in nervous system tone. For thyroid dysregulation, the treatment is the thyroid intervention. For autonomic dysfunction, the interventions are pacing, salt and fluid protocols, compression where appropriate, and specialized autonomic rehabilitation. For blood sugar volatility, dietary timing and composition adjustments can substantially reduce the nocturnal and postprandial adrenaline spikes.
Where peptide approaches may have an adjunctive role is primarily through compounds that support the nervous system's regulatory capacity without the dependence or sedation risks of conventional anxiolytics. Selank has been researched for anxiolytic effects through GABAergic and serotonergic mechanisms and its relationship to tuftsin — a naturally occurring peptide with immunomodulatory properties and effects on stress response. The research is primarily from Russian academic and clinical literature, not yet replicated in large Western trials. It is not FDA-approved. It may have a supporting role within a comprehensive protocol, not as a standalone intervention and not as a substitute for investigating what is causing the anxiety in the first place.
New anxiety in a person who has been stable for decades is a signal from a physiology that is changing, and it deserves to be investigated rather than accepted. The investigation is not complicated. It requires a provider willing to take the word "new" seriously — to treat this as a diagnostic question rather than a symptom to be managed. What changed, when, and in what physiological context is almost always a better question than "what do we give for anxiety." Sometimes the answer is a neurosteroid. Sometimes it's a thyroid. Sometimes it's a virus from eighteen months ago. The anxiety is real in every case. The mechanism is different, and the mechanism determines what addressing it actually looks like.
Frequently asked